Monday Morning's Movers: LGF, MSFT, SRE >>> READ MORE

5 Biotech Stocks That Are Buyout Candidates

Current drug portfolios and pipelines make these biopharma names near-term acquisition targets

      View All  

Ariad Pharmaceuticals (ARIA)

biotech-stocks-ARIA-stockEver heard the term “where there’s smoke, there’s fire”? While the idea of an acquisition of Ariad Pharmaceuticals (ARIA) has been scoffed at and dismissed of late, it’s been so adamantly and repeatedly dismissed, one can’t help but wonder if investors and the media are trying desperately trying to talk themselves out of believing something they don’t want to think is likely … a true contrarian clue.

If you’re not familiar with the company, this might ring a bell — ARIA stock tanked in October when Ariad Pharmaceuticals’ one and only drug, Iclusig, was implicated as the probable cause of blood clotting in the leukemia patients who were taking it.

Though in retrospect it’s clear the market as well as the FDA over-reacted (the drug is back on shelves in the United States, just with a longer list of warnings), the stock has yet to reclaim its pre-plunge highs. ARIA stock is the ultimate contrarian play among the biotech stocks that are also buyout candidates.

Article printed from InvestorPlace Media,

©2017 InvestorPlace Media, LLC